Angiotensins in Alzheimer's disease – friend or foe?

Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 Dannenberg, 1988, Incidence of hypertension in the Framingham Study, Am. J. Public Health, 78, 676, 10.2105/AJPH.78.6.676 Skoog, 2006, Update on hypertension and Alzheimer's disease, Neurol. Res., 28, 605, 10.1179/016164106X130506 Kehoe, 2003, The renin-angiotensin-aldosterone system and Alzheimer's disease?, J. Renin Angiotensin Aldosterone Syst., 4, 80, 10.3317/jraas.2003.017 Papademetriou, 2005, Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature, Geriatrics, 60, 20 Kalman, 2008, [Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study], Neuropsychopharmacol. Hung., 10, 233 Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 Pákáski, 2008, Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease, Neurochem. Int., 53, 103, 10.1016/j.neuint.2008.06.005 Kehoe, 2008, Vol. 9 Hardy, 1997, Amyloid, the presenilins and Alzheimer's disease, Trends Neurosci., 20, 154, 10.1016/S0166-2236(96)01030-2 Tyler, 2002, alpha- and beta-secretase: profound changes in Alzheimer's disease, Biochem. Biophys. Res. Commun., 299, 373, 10.1016/S0006-291X(02)02635-9 Miners, 2008, Aβ-degrading enzymes in Alzheimer's disease, Brain Pathol., 18, 240, 10.1111/j.1750-3639.2008.00132.x Deane, 2009, Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease, CNS Neurol. Disord. Drug Targets, 8, 16, 10.2174/187152709787601867 Weller, 2008, Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease, Brain Pathol., 18, 253, 10.1111/j.1750-3639.2008.00133.x Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 Zlokovic, 2000, Clearance of amyloid beta-peptide from brain: transport or metabolism?, Nat. Med., 6, 718, 10.1038/77397 Walsh, 2007, A beta oligomers – a decade of discovery, J. Neurochem., 101, 1172, 10.1111/j.1471-4159.2006.04426.x Longo, 1966, Behavioral and electroencephalographic effects of atropine and related compounds, Pharmacol. Rev., 18, 965 Davies, 1976, Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2, 1403, 10.1016/S0140-6736(76)91936-X Whitehouse, 1982, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science, 215, 1237, 10.1126/science.7058341 Saxena, 2009, Lipid metabolism and Alzheimer's disease: pathways and possibilities, Expert Opin. Ther. Targets, 13, 331, 10.1517/14728220902738720 Rogers, 2008, The inflammatory response in Alzheimer's disease, J. Periodontol., 79, 1535, 10.1902/jop.2008.080171 Kalback, 2004, Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease, Neurol. Res., 26, 525, 10.1179/016164104225017668 Chiu, 1989, Identification of angiotensin II receptor subtypes, Biochem. Biophys. Res. Commun., 165, 196, 10.1016/0006-291X(89)91054-1 Whitebread, 1989, Preliminary biochemical characterization of two angiotensin II receptor subtypes, Biochem. Biophys. Res. Commun., 163, 284, 10.1016/0006-291X(89)92133-5 Marcheselli, 2008, Renin-angiotensin system and stroke, Neurol. Sci., 29, S277, 10.1007/s10072-008-0963-9 Fyhrquist, 2008, Renin-angiotensin system revisited, J. Intern. Med., 264, 224, 10.1111/j.1365-2796.2008.01981.x Haulica, 2005, Angiotensin peptides and their pleiotropic actions, J. Renin Angiotensin Aldosterone Syst., 6, 121, 10.3317/jraas.2005.018 Stanton, 2003, Potential of renin inhibition in cardiovascular disease, J. Renin Angiotensin Aldosterone Syst., 4, 6, 10.3317/jraas.2003.008 Reaux, 2000, Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure, Biochem. Soc. Trans., 28, 435, 10.1042/0300-5127:0280435 Tabrizchi, 2003, Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders, Drugs, 63, 2185, 10.2165/00003495-200363200-00003 Alison Taylor, 2001, Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes, Neuropsychiatr. Genet., 105, 761, 10.1002/ajmg.10044 Rigat, 1990, An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels, J. Clin. Invest., 86, 1343, 10.1172/JCI114844 Danilov, 1996, Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies, J. Hypertens., 14, 719, 10.1097/00004872-199606000-00007 Cox, 2002, Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides, Hum. Mol. Genet., 11, 2969, 10.1093/hmg/11.23.2969 McKenzie, 2005, SNP haplotypes in the angiotensin I-converting enzyme (ACE) gene: analysis of Nigerian family data using gamete competition models, Ann. Hum. Genet., 69, 227, 10.1046/j.1469-1809.2004.00142.x Villard, 1996, Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis, Am. J. Hum. Genet., 58, 1268 Bertram, 2009, Systematic meta-analysis of Alzheimer disease genetic association studies: the AlzGene database, Nat Genet, 39, 17, 10.1038/ng1934 Kehoe, 1999, Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease, Nat. Genet., 21, 71, 10.1038/5009 Elkins, 2004, Alzheimer disease risk and genetic variation in ACE: a meta-analysis, Neurology, 62, 363, 10.1212/01.WNL.0000106823.72493.FF Kehoe, 2003, Haplotypes extending across ACE are associated with Alzheimer's disease, Hum. Mol. Genet., 12, 859, 10.1093/hmg/ddg094 Lehmann, 2005, Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease, Am. J. Epidemiol., 162, 305, 10.1093/aje/kwi202 Narain, 2000, The ACE gene and Alzheimer's disease susceptibility, J. Med. Genet., 37, 695, 10.1136/jmg.37.9.695 Ioannidis, 2008, Assessment of cumulative evidence on genetic associations: interim guidelines, Int. J. Epidemiol., 37, 120, 10.1093/ije/dym159 Kauwe, 2009, Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta, Neurogenetics, 10, 13, 10.1007/s10048-008-0150-4 Meng, 2006, Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community, Am. J. Hum. Genet., 78, 871, 10.1086/503687 Schjeide, 2009, Assessment of Alzheimer's disease case-control associations using family-based methods, Neurogenetics, 10, 19, 10.1007/s10048-008-0151-3 Kehoe, 2004, Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease, Hum. Genet., 114, 478, 10.1007/s00439-004-1093-y Sleegers, 2005, ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala, Neurobiol. Aging, 26, 1153, 10.1016/j.neurobiolaging.2004.09.011 Lendon, 2002, The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease, Neurosci. Lett., 328, 314, 10.1016/S0304-3940(02)00553-0 Miners, 2009, Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes, Am. J. Transl. Res., 1, 163 Carrasquillo, 2009, Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease, Nat. Genet., 41, 192, 10.1038/ng.305 Coon, 2007, A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease, J. Clin. Psychiatry, 68, 613, 10.4088/JCP.v68n0419 Feulner, 2009, Examination of the current top candidate genes for AD in a genome-wide association study, Mol. Psychiatry Li, 2008, Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease, Arch. Neurol., 65, 45, 10.1001/archneurol.2007.3 Thornton-Wells, 2008, Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis, Genet. Epidemiol., 32, 187, 10.1002/gepi.20294 Edwards, 2009, An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3, Am. J. Med. Genet. B Neuropsychiatr. Genet., 150B, 721, 10.1002/ajmg.b.30899 Lee, 2008, Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci, Arch. Neurol., 65, 1518, 10.1001/archneur.65.11.1518 van Esch, 2008, Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype, J. Hypertens., 26, 706, 10.1097/HJH.0b013e3282f465d2 Gong, 2005, Post-translational modifications of tau protein in Alzheimer's disease, J. Neural Transm., 112, 813, 10.1007/s00702-004-0221-0 Arregui, 1982, Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas, J. Neurochem., 38, 1490, 10.1111/j.1471-4159.1982.tb07930.x Barnes, 1991, Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease, Eur. J. Pharmacol., 200, 289, 10.1016/0014-2999(91)90584-D Kalaria, 1989, Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease, J. Neurochem., 53, 1083, 10.1111/j.1471-4159.1989.tb07399.x McGeer, 1992, Angiotensin-converting enzyme in cortical tissue in Alzheimer's and some other neurological diseases, Dementia, 3, 299 Savaskan, 2001, Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia, Neurobiol. Aging, 22, 541, 10.1016/S0197-4580(00)00259-1 Miners, 2008, Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy, Neuropathol. Appl. Neurobiol., 34, 181, 10.1111/j.1365-2990.2007.00885.x Zubenko, 1986, Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study, Biol. Psychiatry, 21, 1365, 10.1016/0006-3223(86)90328-8 Zubenko, 1985, Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, Brain Res., 328, 215, 10.1016/0006-8993(85)91032-7 Konings, 1993, Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with ‘probable’ Alzheimer's disease, Eur. J. Clin. Chem. Clin. Biochem., 31, 495 Nielsen, 2007, Soluble adhesion molecules and angiotensin-converting enzyme in dementia, Neurobiol. Dis., 26, 27, 10.1016/j.nbd.2006.11.011 Savaskan, 1991, Angiotensin II immunoreactivity in the human striatum and hippocampus of elderly controls and patients with senile dementia of the Alzheimer type and multi-infarct dementia, Dementia, 2, 314 AbdAlla, 2009, Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease, J. Biol. Chem, 284, 6554, 10.1074/jbc.M807746200 Janciauskiene, 2009, A link between sICAM-1, ACE and parietal blood flow in the aging brain, Neurobiol. Aging, 30, 1504, 10.1016/j.neurobiolaging.2007.08.025 Hu, 2001, Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity, J. Biol. Chem., 276, 47863, 10.1074/jbc.M104068200 Hemming, 2005, Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor, J. Biol. Chem., 280, 37644, 10.1074/jbc.M508460200 Oba, 2005, The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide, Eur. J. Neurosci, 21, 733, 10.1111/j.1460-9568.2005.03912.x Toropygin, 2008, Rapid Commun. Mass Spectrom, 22, 231, 10.1002/rcm.3357 Eckman, 2006, Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme, but not angiotensin-converting enzyme, J. Biol. Chem., 281, 30471, 10.1074/jbc.M605827200 Hemming, 2007, Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease, Neurobiol. Dis., 26, 273, 10.1016/j.nbd.2007.01.004 Zou, 2007, Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition, J. Neurosci., 27, 8628, 10.1523/JNEUROSCI.1549-07.2007 Hou, 2008, Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease, Chin. Med. J. (Engl.), 121, 2320, 10.1097/00029330-200811020-00019 Wang, 2007, Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease, J. Clin. Invest., 117, 3393, 10.1172/JCI31547 Mogi, 2008, Telmisartan prevented cognitive decline partly due to PPAR-gamma activation, Biochem. Biophys. Res. Commun., 375, 446, 10.1016/j.bbrc.2008.08.032 Du, 2009, Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice, Biochem. Biophys. Res. Commun., 384, 357, 10.1016/j.bbrc.2009.04.148 Santos, 2005, Peroxisomal proliferation protects from beta-amyloid neurodegeneration, J. Biol. Chem., 280, 41057, 10.1074/jbc.M505160200 AbdAlla, 2009, Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration, J. Biol. Chem., 284, 6566, 10.1074/jbc.M808277200 Sun, 2008, Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-[beta] peptides, Eur. J. Pharmacol., 588, 18, 10.1016/j.ejphar.2008.03.058 Barnes, 1992, Angiotensin-converting enzyme inhibition, angiotensin, and cognition, J. Cardiovasc. Pharmacol., 19, S63, 10.1097/00005344-199219006-00011 Hamdi, 2004, A genetic variant of ACE increases cell survival: a new paradigm for biology and disease, Biochem. Biophys. Res. Commun., 318, 187, 10.1016/j.bbrc.2004.04.004 Suzuki, 2003, Inflammation and angiotensin II, Int. J. Biochem. Cell Biol., 35, 881, 10.1016/S1357-2725(02)00271-6 Wosik, 2007, Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis, J. Neurosci, 27, 9032, 10.1523/JNEUROSCI.2088-07.2007 Gard, 2004, Angiotensin and Alzheimer's disease: therapeutic prospects, Expert Rev. Neurother., 4, 87, 10.1586/14737175.4.1.87 Chai, 2008, Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase, BMC Neurosci., 9, S14, 10.1186/1471-2202-9-S2-S14 Forette, 1998, Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, Lancet, 352, 1347, 10.1016/S0140-6736(98)03086-4 Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch. Intern. Med., 163, 1069, 10.1001/archinte.163.9.1069 Peters, 2008, Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial, Lancet Neurol., 7, 683, 10.1016/S1474-4422(08)70143-1 Ohrui, 2004, Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan, J. Am. Geriatr. Soc., 52, 649, 10.1111/j.1532-5415.2004.52178_7.x Khachaturian, 2006, Antihypertensive medication use and incident Alzheimer disease: The Cache County Study, Arch. Neurol., 63, 686, 10.1001/archneur.63.5.noc60013 Wolozin, B. et al. (2008) Use of angiotensin receptor blockers is associated with lower incidence and progression of Alzheimer's disease. In Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) July 26–31, 2008 McCormick Place, Chicago, IL, p. T118, Supplement to Alzheimer's & Dementia The Journal of the Alzheimer's Association, Elsevier Weiner, 1992, ACE inhibitor lacks acute effect on cognition or brain blood flow in Alzheimer's disease, Drug Dev. Res., 26, 467, 10.1002/ddr.430260410 Sudilovsky, 1993, A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 7, 105, 10.1097/00002093-199307020-00006 Louis, 1999, Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery, J. Hypertens., 17, 1813, 10.1097/00004872-199917121-00005 Ohrui, 2004, Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression, Neurology, 63, 1324, 10.1212/01.WNL.0000140705.23869.E9 Hajjar, 2005, Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population, J. Gerontol. A Biol. Sci. Med. Sci., 60, 67, 10.1093/gerona/60.1.67 He, 2006, ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease, Neurology, 67, 1309, 10.1212/01.wnl.0000238102.04582.ec Rozzini, 2006, Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment, Int. J. Geriatr. Psychiatry, 21, 550, 10.1002/gps.1523 Kehoe, 2007, Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?, Lancet Neurol., 6, 373, 10.1016/S1474-4422(07)70077-7